GlassScriptPhysician profile
Loris A Tisocco
NPI 1205896008
$1,320.24
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $40.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $192.45 | 2019 | |
| Pfizer INC. | $191.38 | 2019 | |
| Lilly USA, LLC | $138.11 | 2019 | |
| Encore Dermatology INC. | $112.93 | 2019 | |
| Abbvie INC. | $93.23 | 2019 | |
| Galderma Laboratories, L.P. | $80.69 | 2019 | |
| Janssen Biotech, INC. | $76.74 | 2019 | |
| Celgene Corporation | $53.73 | 2019 | |
| Ucb, INC. | $52.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $49.04 | 2019 | |
| Journey Medical Corporation | $45.81 | 2019 | |
| Strata Skin Sciences, INC. | $39.63 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.95 | 2019 | |
| Almirall LLC | $24.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.74 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $22.59 | 2019 | |
| Prugen, INC. Pharmaceuticals | $21.77 | 2019 | |
| Dusa Pharmaceuticals, INC. | $20.87 | 2019 | |
| Amgen INC. | $20.20 | 2020 | |
| Genzyme Corporation | $14.10 | 2019 | |
| Promius Pharma LLC | $12.04 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loris Tisocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.